Small-particle Inhaled Corticosteroid as First-line or Step-up Controller Therapy in Childhood Asthma

Journal of Allergy and Clinical Immunology: In Practice

Volumn 3, Issue 5, 2015, Pages 721-731.e16

  van Aalderen, Willem M C ^a   Grigg, Jonathan ^b   Guilbert, Theresa W ^c   Roche, Nicolas ^d   Israel, Elliot ^e   Martin, Richard J ^f   Colice, Gene ^g   Postma, Dirkje S ^h   Hillyer, Elizabeth V ⁱ   Burden, Anne ⁱ   Thomas, Victoria ⁱ   von Ziegenweidt, Julie ⁱ   Price, David ^i,j  

^a EMMA CHILDREN S HOSPITAL   (Netherlands)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^d Institut Cochin   (France)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF COLORADO   (United States)

^g GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁱ Research in Real Life Ltd   (United Kingdom)

^j UNIVERSITY OF ABERDEEN   (United Kingdom)

more..

Author keywords

Asthma; Childhood; Fluticasone; Inhaled corticosteroid; Long acting 2 agonist; Small particle beclomethasone; Step up therapy

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MICROSPHERE;

ARTICLE; ASTHMA; CHILD; COHORT ANALYSIS; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RISK; PRESCRIPTION; RISK ASSESSMENT; COMPARATIVE STUDY; DOSE CALCULATION; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; PARTICLE SIZE; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ASTHMA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG DOSAGE CALCULATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICROSPHERES; PARTICLE SIZE; TREATMENT OUTCOME;

EID: 84941215491     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2015.04.012     Document Type: Article

References (61)

1. Adams N., Lasserson T.J., Cates C.J., Jones P.W. Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2007, CD002310.
2. Lasserson T.J., Cates C.K., Jones A.B., Steele E.H., White J. Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database Syst Rev 2006, CD005309.
3. Kramer S., Rottier B.L., Scholten R.J., Boluyt N. Ciclesonide versus other inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 2013, 2:CD010352.
4. Ducharme F.M., Ni Chroinin M., Greenstone I., Lasserson T.J. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev 2010, CD005533.
5. Cates C.J., Oleszczuk M., Stovold E., Wieland L.S. Safety of regular formoterol or salmeterol in children with asthma: an overview of Cochrane reviews. Cochrane Database Syst Rev 2012, 10:CD010005.
6. Lenney W., McKay A.J., Tudur Smith C., Williamson P.R., James M., Price D. Management of Asthma in School age Children On Therapy (MASCOT): a randomised, double-blind, placebo-controlled, parallel study of efficacy and safety. Health Technol Assess 2013, 17:1-218.
7. Price D., Bateman E.D., Chisholm A., Papadopoulos N.G., Bosnic-Anticevich S., Pizzichini E., et al. Complementing the randomized controlled trial evidence base: evolution not revolution. Ann Am Thorac Soc 2014, 11:S92-S98.
8. Colice G., Martin R.J., Israel E., Roche N., Barnes N., Burden A., et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and fluticasone. J Allergy Clin Immunol 2013, 132:45-54. e10.
9. Price D., Martin R.J., Barnes N., Dorinsky P., Israel E., Roche N., et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010, 126:511-518. e1-10.
10. Cripps A., Riebe M., Schulze M., Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000, 94:S3-S9.
11. Shi Y., Aledia A.S., Tatavoosian A.V., Vijayalakshmi S., Galant S.P., George S.C. Relating small airways to asthma control by using impulse oscillometry in children. J Allergy Clin Immunol 2012, 129:671-678.
12. van Schayck C.P., Donnell D. The efficacy and safety of QVAR (hydrofluoroalkane-beclometasone diproprionate extrafine aerosol) in asthma (part 2): clinical experience in children. Int J Clin Pract 2004, 58:786-794.
13. Leach C.L., Davidson P.J., Hasselquist B.E., Boudreau R.J. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med 2005, 18:379-385.
14. Leach C.L., Davidson P.J., Hasselquist B.E., Boudreau R.J. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002, 122:510-516.
15. Leach C.L., Davidson P.J., Boudreau R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998, 12:1346-1353.
16. Devadason S.G., Huang T., Walker S., Troedson R., Le Souef P.N. Distribution of technetium-99m-labelled QVAR delivered using an Autohaler device in children. Eur Respir J 2003, 21:1007-1011.
17. Roller C.M., Zhang G., Troedson R.G., Leach C.L., Le Souef P.N., Devadason S.G. Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children. Eur Respir J 2007, 29:299-306.
18. Costa-Katz C.L., Livnat G., Hakim F., Vilozni D., Bentur Y., Bentur L. The effect of beclomethasone dipropionate in ultrafine particles on bronchial hyper-reactivity in young children. Acta Paediatr 2012, 101:e219-e224.
19. Eid N., Morton R. Lung function changes in asthmatic children treated with HFA-BDP. Pediatr Pulmonol 2011, 46:837-841.
20. Robroeks C.M., van de Kant K.D., van Vliet D., Kester A.D., Hendriks H.J., Damoiseaux J.G., et al. Comparison of the anti-inflammatory effects of extra-fine hydrofluoroalkane-beclomethasone vs fluticasone dry powder inhaler on exhaled inflammatory markers in childhood asthma. Ann Allergy Asthma Immunol 2008, 100:601-607.
21. van Aalderen W.M., Price D., De Baets F.M., Price J. Beclometasone dipropionate extrafine aerosol versus fluticasone propionate in children with asthma. Respir Med 2007, 101:1585-1593.
22. Castro-Rodriguez J.A., Rodrigo G.J. A systematic review of long-acting beta2-agonists versus higher doses of inhaled corticosteroids in asthma. Pediatrics 2012, 130:e650-e657.
23. Lemanske R.F., Mauger D.T., Sorkness C.A., Jackson D.J., Boehmer S.J., Martinez F.D., et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010, 362:975-985.
24. Clinical Practice Research Datalink. Available from: Accessed April 10, 2014. http://www.cprd.com/home/.
25. Optimum Patient Care Research Database (OPCRD). Available from: Accessed April 10, 2014. http://www.optimumpatientcare.org/Html_Docs/OPCRD.html.
26. Barnes N., Price D., Colice G., Chisholm A., Dorinsky P., Hillyer E.V., et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy 2011, 41:1521-1532.
27. Price D., Hillyer E.V., van der Molen T. Efficacy versus effectiveness trials: informing guidelines for asthma management. Curr Opin Allergy Clin Immunol 2013, 13:50-57.
28. Akinbami L.J., Sullivan S.D., Campbell J.D., Grundmeier R.W., Hartert T.V., Lee T.A., et al. Asthma outcomes: healthcare utilization and costs. J Allergy Clin Immunol 2012, 129:S49-64.
29. Kozyrskyj A.L., Dahl M.E., Ungar W.J., Becker A.B., Law B.J. Antibiotic treatment of wheezing in children with asthma: what is the practice?. Pediatrics 2006, 117:e1104-e1110.
30. Reddel H.K., Taylor D.R., Bateman E.D., Boulet L.P., Boushey H.A., Busse W.W., et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180:59-99.
31. Research in Real Life: standard operating procedures. Available from: Accessed April 10, 2014. http://www.optimumpatientcare.org/Docs/SOP%20Observational%20Database%20Studies.pdf.
32. Benjamini Y., Liu W. A distribution-free multiple test procedure that controls the false discovery rate. RP-SOR-99-3 1999, Department of Statistics and O.R., Tel Aviv University, Tel Aviv, Israel.
33. Williams L.K., Peterson E.L., Wells K., Ahmedani B.K., Kumar R., Burchard E.G., et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol 2011, 128:1185-1191.e2.
34. Ivanova J.I., Bergman R., Birnbaum H.G., Colice G.L., Silverman R.A., McLaurin K. Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. J Allergy Clin Immunol 2012, 129:1229-1235.
35. Amirav I., Newhouse M.T. Deposition of small particles in the developing lung. Paediatr Respir Rev 2012, 13:73-78.
36. Bacharier L.B., Boner A., Carlsen K.H., Eigenmann P.A., Frischer T., Gotz M., et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 2008, 63:5-34.
37. British Thoracic Society (BTS), Scottish Intercollegiate Guidelines Network (SIGN). British Guideline on the Management of Asthma, May 2008, revised Jan 2012. Available from: Accessed April 10, 2014. http://www.sign.ac.uk/guidelines/fulltext/101/index.html.
38. Chowdhury B.A., Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med 2010, 362:1169-1171.
39. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, revised 2014. Available from: Accessed June 10, 2014. http://www.ginasthma.org.
40. Martinez F.D., Chinchilli V.M., Morgan W.J., Boehmer S.J., Lemanske R.F., Mauger D.T., et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 2011, 377:650-657.
41. Allen D.B. Effects of inhaled steroids on growth, bone metabolism and adrenal function. Expert Rev Respir Med 2007, 1:65-74.
42. Pruteanu A.I., Chauhan B.F., Zhang L., Prietsch S.O., Ducharme F.M. Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. Cochrane Database Syst Rev 2014, 7:CD009878.
43. Kelly H.W., Sternberg A.L., Lescher R., Fuhlbrigge A.L., Williams P., Zeiger R.S., et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012, 367:904-912.
44. Joffe M.M., Rosenbaum P.R. Invited commentary: propensity score. Am J Epidemiol 1999, 150:327-333.
45. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Available from: Accessed July 31, 2014. http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.
46. Switching to CFC-free beclometasone for asthma. Drug Ther Bull 2008, 46:46-48.
47. von Elm E., Altman D.G., Egger M., Pocock S.J., Gotzsche P.C., Vandenbroucke J.P. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007, 370:1453-1457.
48. Vandenbroucke J.P., von Elm E., Altman D.G., Gotzsche P.C., Mulrow C.D., Pocock S.J., et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007, 4:e297.
49. Price D., Hillyer E.V., van der Molen T. Efficacy versus effectiveness trials: informing guidelines for asthma management. Curr Opin Allergy Clin Immunol 2013, 13:50-57.
50. Khan N.F., Harrison S.E., Rose P.W. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010, 60:e128-e136.
51. Wood L., Martinez C. The general practice research database: role in pharmacovigilance. Drug Saf 2004, 27:871-881.
52. Wong I.C., Murray M.L. The potential of UK clinical databases in enhancing paediatric medication research. Br J Clin Pharmacol 2005, 59:750-755.
53. Price D., Martin R.J., Barnes N., Dorinsky P., Israel E., Roche N., et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010, 126:511-518. e1-10.
54. Bhaskaran K., Forbes H.J., Douglas I., Leon D.A., Smeeth L. Representativeness and optimal use of body mass index (BMI) in the UK Clinical Practice Research Datalink (CPRD). BMJ Open 2013, 3:e003389.
55. Clinical Practice Research Datalink. Available from: Accessed April 10, 2014. http://www.cprd.com/home/.
56. Optimum Patient Care Research Database (OPCRD). Available from: Accessed April 10, 2014. http://www.optimumpatientcare.org/Html_Docs/OPCRD.html.
57. Hansell A., Hollowell J., Nichols T., McNiece R., Strachan D. Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4). Thorax 1999, 54:413-419.
58. Jones R.C.M., Price D., Ryan D., Sims E.J., von Ziegenweidt J., Mascarenhas L., et al. Opportunities to diagnose chronic obstructive pulmonary disease in routine care in the UK: a retrospective study of a clinical cohort. Lancet Respir Med 2014, 2:267-276.
59. Switching to CFC-free beclometasone for asthma. Drug Ther Bull 2008, 46:46-48.
60. British Thoracic Society (BTS), Scottish Intercollegiate Guidelines Network (SIGN). British Guideline on the Management of Asthma, May 2008, revised Jan 2012. Available from: Accessed April 10, 2014. http://www.sign.ac.uk/guidelines/fulltext/101/index.html.
61. Benjamini Y., Liu W. A distribution-free multiple test procedure that controls the false discovery rate. RP-SOR-99-3 1999, Department of Statistics and O.R., Tel Aviv University, Tel Aviv, Israel.